Format

Send to

Choose Destination
Lancet Haematol. 2019 Apr;6(4):e170-e171. doi: 10.1016/S2352-3026(19)30025-0.

Effective oral hypomethylating drugs in intermediate-risk or high-risk myelodysplasia: a breakthrough?

Author information

1
Nijmegen Center for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands. Electronic address: Theo.deWitte@radboudumc.nl.

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center